Correlation Between Bristol Myers and Takeda Pharmaceutical

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Takeda Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Takeda Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Takeda Pharmaceutical Co, you can compare the effects of market volatilities on Bristol Myers and Takeda Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Takeda Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Takeda Pharmaceutical.

Diversification Opportunities for Bristol Myers and Takeda Pharmaceutical

0.66

Correlation Coefficient

Bristol Myers  Takeda Pharmaceutical

Poor diversification

The 3 months correlation between Bristol and Takeda is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Takeda Pharmaceutical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Takeda Pharmaceutical and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Takeda Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Takeda Pharmaceutical has no effect on the direction of Bristol Myers i.e., Bristol Myers and Takeda Pharmaceutical go up and down completely randomly.

Pair Corralation between Bristol Myers and Takeda Pharmaceutical

Considering the 90-day investment horizon Bristol Myers is expected to generate 2.02 times less return on investment than Takeda Pharmaceutical. In addition to that, Bristol Myers is 1.38 times more volatile than Takeda Pharmaceutical Co. It trades about 0.07 of its total potential returns per unit of risk. Takeda Pharmaceutical Co is currently generating about 0.2 per unit of volatility. If you would invest  1,317  in Takeda Pharmaceutical Co on December 29, 2024 and sell it today you would earn a total of  188.00  from holding Takeda Pharmaceutical Co or generate 14.27% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Takeda Pharmaceutical Co

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Takeda Pharmaceutical

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Takeda Pharmaceutical Co are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain basic indicators, Takeda Pharmaceutical disclosed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Bristol Myers and Takeda Pharmaceutical

The main advantage of trading using opposite Bristol Myers and Takeda Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Takeda Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Takeda Pharmaceutical will offset losses from the drop in Takeda Pharmaceutical's long position.

The idea behind Bristol Myers Squibb and Takeda Pharmaceutical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.